• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Investigation Report on China Trastuzumab Market, 2009-2018 Product Image

Investigation Report on China Trastuzumab Market, 2009-2018

  • ID: 2759316
  • February 2014
  • Region: China
  • 40 Pages
  • China Research & Intelligence

Trastuzumab is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers. Trastuzumab has a major impact in the treatment of HER2-positive metastatic breast cancers.

In China, less than 10% of women can get mammary diseases inspection every year for the limitation of medical conditions and lack of knowledge. Therefore, only 20% of breast cancers is detected at an early stage in China while 80% is detected at an early stage in the U.S.A.

The incidence of breast cancers ranks the first in malignant tumors. According to incomplete statistics, the incidence number of breast cancers exceeds 200,000 every year in China. By the end of 2013, the number of living breast cancer patients exceeded 500,000, above 1/3 of which were metastatic breast cancers. The incidence and mortality rates of breast cancers differ from urban to rural areas in China. In recent 10 years, the incidence of breast cancers in cities obviously increases but the mortality rate remains stable. However, the incidence and mortality rates of breast cancers in rural areas present obvious uprising trend. The number of breast cancer patients in cities is READ MORE >

1 Relevant Concepts of Trastuzumab
1.1 Indication
1.2 Sales Status on the Global Market

2 Market Overview of Trastuzumab in China, 2009-2013
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size

3 Investigation on Sales Value of Trastuzumab in China, 2009-2013
3.1 Total Sales Value
3.2 Sales Value by Region

4 Investigation on Market Share of Major Trastuzumab Manufacturers in China, 2009-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Investigation on Market Size of Trastuzumab by Dosage Form in China , 2009-2013
5.1 Market Share by Sales Value and Dosage Form
5.2 Market Share by Sales Volume and Dosage Form

6 Reference Price of Trastuzumab in Hospital Market in China, 2013
6.1 Trastuzumab Produced by Shanghai Roche (Brand Name: Herceptin)
6.2 Trastuzumab Produced by GENENTECH (Brand Name: Herceptin)

7 Analysis on Major Trastuzumab Manufacturers in China, 2009-2013
7.1 Shanghai Roche Pharmaceuticals Ltd.
7.2 GENENTECH (Subsidiary of Roche)

8 Prospect of China Trastuzumab Market, 2014-2018
8.1 Forecast on Incidence of Mammary Cancer
8.2 Forecast on Market Size
8.3 Forecast on Competition Pattern

Selected Charts

Chart Trastuzumab Products Approved to Market in China, 2014
Chart Forecast on Market Size of Hospital-use Trastuzumab in China, 2014-2018
Chart Sales Value of Trastuzumab in Global Market, 2009-2013
Chart Sales Value of Trastuzumab in Hospital Market in China, 2009-2013
Chart Sales Value of Trastuzumab by Region in China, 2009-2013
Chart Market Share of Trastuzumab Enterprises by Sales Value in China, 2009-2013
Chart Price of Trastuzumab Produced by GENENTECH(US) in Hospital Market, 2009-2013
Chart Price of Trastuzumab Produced by Shanghai Roche in Hospital Market, 2009-2013

- GENENTECH (Subsidiary of Roche)
- Shanghai Roche Pharmaceuticals Ltd.

Note: Product cover images may vary from those shown

ALSO AVAILABLE IN THE FOLLOWING LANGUAGES

RELATED PRODUCTS

Our Clients

Our clients' logos